LncRNA MEG3 Inhibits Tumor Progression by Modulating Macrophage Phenotypic Polarization via miR-145-5p/DAB2 Axis in Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Cai Y, Lyu T, Li H, et al. LncRNA CEBPA-DT promotes liver cancer metastasis through DDR2/β-catenin activation via interacting with hnRNPC. J Exp Clin Cancer Res. 2022;41(1):335. doi:10.1186/s13046-022-02544-6
   PubMed Web of Science ®Google Scholar
• Marrero JA, Fontana RJ, Fu S, et al. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol. 2005;42(2):218–224. doi:10.1016/j.jhep.2004.10.005
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, et al. Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol. 2016;25(2):74–85. doi:10.1016/j.suronc.2016.03.002
   PubMed Web of Science ®Google Scholar
• Lurje I, Czigany Z, Bednarsch J, et al. Treatment strategies for hepatocellular carcinoma ⁻ a multidisciplinary approach. Int J Mol Sci. 2019;20(6):1465. doi:10.3390/ijms20061465
   PubMed Web of Science ®Google Scholar
• Finn RS, Zhu AX, Farah W, et al. Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: a systematic review and meta-analysis. Hepatology. 2018;67(1):422–435. doi:10.1002/hep.29486
   PubMed Web of Science ®Google Scholar
• Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346–354. doi:10.1038/nature12626
   PubMed Web of Science ®Google Scholar
• Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753. doi:10.1016/j.pharmthera.2020.107753
   PubMed Web of Science ®Google Scholar
• Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science. 2013;339(6117):286–291. doi:10.1126/science.1232227
   PubMed Web of Science ®Google Scholar
• Wang Y-C, He F, Feng F, et al. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res. 2010;70(12):4840–4849. doi:10.1158/0008-5472.CAN-10-0269
   PubMed Web of Science ®Google Scholar
• Zhou D, Luan J, Huang C, et al. Tumor-associated macrophages in hepatocellular carcinoma: friend or foe? Gut Liver. 2021;15(4):500–516. doi:10.5009/gnl20223
   PubMed Web of Science ®Google Scholar
• Wang Y, Gao R, Li J, et al. Downregulation of hsa_circ_0074854 suppresses the migration and invasion in hepatocellular carcinoma via interacting with HuR and via suppressing exosomes-mediated macrophage M2 polarization. Int J Nanomedicine. 2021;16:2803–2818. doi:10.2147/IJN.S284560
   PubMed Web of Science ®Google Scholar
• Yin Z, Ma T, Lin Y, et al. Retracted: IL-6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma. J Cell Biochem. 2018;119(11):9419–9432. doi:10.1002/jcb.27259
   PubMed Web of Science ®Google Scholar
• Klichinsky M, Ruella M, Shestova O, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947–953. doi:10.1038/s41587-020-0462-y
   PubMed Web of Science ®Google Scholar
• Qiu Y, Chen T, Hu R, et al. Next frontier in tumor immunotherapy: macrophage-mediated immune evasion. Biomark Res. 2021;9(1):72. doi:10.1186/s40364-021-00327-3
   PubMed Web of Science ®Google Scholar
• Wang L, Cho KB, Li Y, et al. Long noncoding RNA (lncRNA)-mediated competing endogenous RNA networks provide novel potential biomarkers and therapeutic targets for colorectal cancer. Int J Mol Sci. 2019;20(22):5758.
   PubMed Web of Science ®Google Scholar
• Tan Y-T, Lin J-F, Li T, et al. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Commun. 2021;41(2):109–120. doi:10.1002/cac2.12108
   PubMed Web of Science ®Google Scholar
• Chan JJ, Tay Y. Noncoding RNA: RNA regulatory networks in cancer. Int J Mol Sci. 2018;19(5):1310. doi:10.3390/ijms19051310
   PubMed Web of Science ®Google Scholar
• Chen L, Qiu C-H, Chen Y, et al. LncRNA SNHG16 drives proliferation, migration, and invasion of lung cancer cell through modulation of miR-520/VEGF axis. Eur Rev Med Pharmacol Sci. 2020;24(18):9522–9531. doi:10.26355/eurrev_202009_23037
   PubMed Web of Science ®Google Scholar
• Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteomics Bioinformatics. 2016;14(1):42–54. doi:10.1016/j.gpb.2015.09.006
   PubMed Web of Science ®Google Scholar
• Zhang L, Tao H, Li J, et al. Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma. Aging. 2021;13(12):15990–16008. doi:10.18632/aging.203056
   PubMedGoogle Scholar
• Teng F, Zhang J-X, Chang Q-M, et al. LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020;39(1):235. doi:10.1186/s13046-020-01739-z
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang L, Chen T, et al. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis. Mol Cancer. 2019;18(1):28. doi:10.1186/s12943-019-0957-7
   PubMed Web of Science ®Google Scholar
• Xu J, Wang X, Zhu C, et al. A review of current evidence about lncRNA MEG3: a tumor suppressor in multiple cancers. Front Cell Dev Biol. 2022;10:997633. doi:10.3389/fcell.2022.997633
   PubMed Web of Science ®Google Scholar
• Du Y, Geng G, Zhao C, et al. LncRNA MEG3 promotes cisplatin sensitivity of cervical cancer cells by regulating the miR-21/PTEN axis. BMC Cancer. 2022;22(1):1145. doi:10.1186/s12885-022-10188-0
   PubMed Web of Science ®Google Scholar
• Wei GH, Wang X. lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21(17):3850–3856.
   PubMed Web of Science ®Google Scholar
• Wu M, Huang Y, Chen T, et al. LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/ QKI-5 axis. J Cell Mol Med. 2019;23(1):29–38. doi:10.1111/jcmm.13658
   PubMed Web of Science ®Google Scholar
• Yang Z, Wang Z, Duan Y. LncRNA MEG3 inhibits non-small cell lung cancer via interaction with DKC1 protein. Oncol Lett. 2020;20(3):2183–2190. doi:10.3892/ol.2020.11770
   PubMed Web of Science ®Google Scholar
• Sun K-X, Wu -D-D, Chen S, et al. LncRNA MEG3 inhibit endometrial carcinoma tumorigenesis and progression through PI3K pathway. Apoptosis. 2017;22(12):1543–1552. doi:10.1007/s10495-017-1426-7
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu J, Lv Y, et al. LncRNA meg3 suppresses hepatocellular carcinoma in vitro and vivo studies. Am J Transl Res. 2019;11(7):4089–4099.
   PubMed Web of Science ®Google Scholar
• Toda G, Yamauchi T, Kadowaki T, et al. Preparation and culture of bone marrow-derived macrophages from mice for functional analysis. STAR Protoc. 2021;2(1):100246. doi:10.1016/j.xpro.2020.100246
   PubMedGoogle Scholar
• Weischenfeldt J, Porse B. Bone Marrow-Derived Macrophages (BMM): isolation and applications. CSH Protoc. 2008;2008:pdb.prot5080. doi:10.1101/pdb.prot5080
   PubMedGoogle Scholar
• Zong S, Dai W, Guo X, et al. LncRNA-SNHG1 promotes macrophage M2-like polarization and contributes to breast cancer growth and metastasis. Aging. 2021;13(19):23169–23181. doi:10.18632/aging.203609
   PubMedGoogle Scholar
• Zhou C, Liu C, Liu W, et al. SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway. Theranostics. 2020;10(10):4627–4643. doi:10.7150/thno.42869
   PubMed Web of Science ®Google Scholar
• Dong J, Teng F, Guo W, et al. lncRNA SNHG8 promotes the tumorigenesis and metastasis by sponging miR-149-5p and predicts tumor recurrence in hepatocellular carcinoma. Cell Physiol Biochem. 2018;51(5):2262–2274. doi:10.1159/000495871
   PubMedGoogle Scholar
• Oura K, Morishita A, Tani J, et al. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review. Int J Mol Sci. 2021;22(11):5801. doi:10.3390/ijms22115801
   PubMed Web of Science ®Google Scholar
• Guizhen Z, Guanchang J, Liwen L, et al. The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy. Front Endocrinol. 2022;13:918869. doi:10.3389/fendo.2022.918869
   PubMed Web of Science ®Google Scholar
• Sas Z, Cendrowicz E, Weinhäuser I, et al. Tumor microenvironment of hepatocellular carcinoma: challenges and opportunities for new treatment options. Int J Mol Sci. 2022;23(7):3778. doi:10.3390/ijms23073778
   PubMed Web of Science ®Google Scholar
• Wang H, Yung MM, Ngan HY, Chan KK, Chan DW. The impact of the tumor microenvironment on macrophage polarization in cancer metastatic progression. Int J Mol Sci. 2021;22(12):6560.
   PubMed Web of Science ®Google Scholar
• Boutilier AJ, Elsawa SF. Macrophage polarization states in the tumor microenvironment. Int J Mol Sci. 2021;22(13):6995. doi:10.3390/ijms22136995
   PubMed Web of Science ®Google Scholar
• Min L, Wang H, Qi H. Astragaloside IV inhibits the progression of liver cancer by modulating macrophage polarization through the TLR4/NF-κB/STAT3 signaling pathway. Am J Transl Res. 2022;14(3):1551–1566.
   PubMed Web of Science ®Google Scholar
• Liu H, Wang M, Jin Z, et al. FNDC5 induces M2 macrophage polarization and promotes hepatocellular carcinoma cell growth by affecting the PPARγ/NF-κB/NLRP3 pathway. Biochem Biophys Res Commun. 2021;582:77–85. doi:10.1016/j.bbrc.2021.10.041
   PubMed Web of Science ®Google Scholar
• Wang LP, Lin J, Ma X-Q, et al. Exosomal DLX6-AS1 from hepatocellular carcinoma cells induces M2 macrophage polarization to promote migration and invasion in hepatocellular carcinoma through microRNA-15a-5p/CXCL17 axis. J Exp Clin Cancer Res. 2021;40(1):177. doi:10.1186/s13046-021-01973-z
   PubMed Web of Science ®Google Scholar
• Tian X, Wu Y, Yang Y, et al. Long noncoding RNA LINC00662 promotes M2 macrophage polarization and hepatocellular carcinoma progression via activating Wnt/β-catenin signaling. Mol Oncol. 2020;14(2):462–483. doi:10.1002/1878-0261.12606
   PubMed Web of Science ®Google Scholar
• Wang X, Zhou Y, Dong K, et al. Exosomal lncRNA HMMR-AS1 mediates macrophage polarization through miR −147a/ ARID3A axis under hypoxia and affects the progression of hepatocellular carcinoma. Environ Toxicol. 2022;37(6):1357–1372. doi:10.1002/tox.23489
   PubMed Web of Science ®Google Scholar
• Dong H, Zhang Y, Xu Y, et al. Downregulation of long non-coding RNA MEG3 promotes proliferation, migration, and invasion of human hepatocellular carcinoma cells by upregulating TGF-β1. Acta Biochim Biophys Sin. 2019;51(6):645–652. doi:10.1093/abbs/gmz046
   Google Scholar
• Liu Z, Chen JY, Zhong Y, et al. lncRNA MEG3 inhibits the growth of hepatocellular carcinoma cells by sponging miR-9-5p to upregulate SOX11. Braz J Med Biol Res. 2019;52(10):e8631. doi:10.1590/1414-431x20198631
   PubMed Web of Science ®Google Scholar
• Li M, Liao H, Wu J, et al. Long noncoding RNA matrilineal expression gene 3 inhibits hepatocellular carcinoma progression by targeting microRNA-5195-3p and regulating the expression of forkhead box O1. Bioengineered. 2021;12(2):12880–12890. doi:10.1080/21655979.2021.2005986
   PubMed Web of Science ®Google Scholar
• Kadkhoda S, Ghafouri-Fard S. Function of miRNA-145-5p in the pathogenesis of human disorders. Pathol Res Pract. 2022;231:153780. doi:10.1016/j.prp.2022.153780
   PubMed Web of Science ®Google Scholar
• Wang S, Wang T, Gu P. microRNA-145-5p inhibits migration, invasion, and metastasis in hepatocellular carcinoma by inhibiting ARF6. Cancer Manag Res. 2021;13:3473–3484. doi:10.2147/CMAR.S300678
   PubMed Web of Science ®Google Scholar
• Gu X, Zhang J, Ran Y, et al. Circular RNA hsa_circ_101555 promotes hepatocellular carcinoma cell proliferation and migration by sponging miR-145-5p and regulating CDCA3 expression. Cell Death Dis. 2021;12(4):356. doi:10.1038/s41419-021-03626-7
   PubMed Web of Science ®Google Scholar
• Dong G, Zhang S, Shen S, et al. SPATS2, negatively regulated by miR-145-5p, promotes hepatocellular carcinoma progression through regulating cell cycle. Cell Death Dis. 2020;11(10):837. doi:10.1038/s41419-020-03039-y
   PubMed Web of Science ®Google Scholar
• Tsai H-J, Huang C-L, Chang Y-W, et al. Disabled-2 is required for efficient hemostasis and platelet activation by thrombin in mice. Arterioscler Thromb Vasc Biol. 2014;34(11):2404–2412. doi:10.1161/ATVBAHA.114.302602
   PubMed Web of Science ®Google Scholar
• Karam JA, Shariat SF, Huang H-Y, et al. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Clin Cancer Res. 2007;13(15 Pt 1):4400–4406. doi:10.1158/1078-0432.CCR-07-0287
   PubMed Web of Science ®Google Scholar
• Rosenbauer F, Kallies A, Scheller M, et al. Disabled-2 is transcriptionally regulated by ICSBP and augments macrophage spreading and adhesion. EMBO J. 2002;21(3):211–220. doi:10.1093/emboj/21.3.211
   PubMed Web of Science ®Google Scholar
• Zhou J, Scholes J, Hsieh JT. Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer. J Biol Chem. 2003;278(9):6936–6941. doi:10.1074/jbc.M210628200
   PubMed Web of Science ®Google Scholar
• Wang H, Dong S, Liu Y, et al. DAB2 suppresses gastric cancer migration by regulating the Wnt/β-catenin and Hippo-YAP signaling pathways. Transl Cancer Res. 2020;9(2):1174–1184. doi:10.21037/tcr.2019.12.96
   PubMed Web of Science ®Google Scholar